“The old ways aren't working any more. Maybe the whole way we go about developing antibiotics needs to change.” So says John Tomayko, MD, the former senior director of clinical development in the Infectious Diseases Therapeutic Unit at GlaxoSmithKline PLC, who at the start of September 2015 became chief medical officer of Spero Therapeutics LLC. Glaxo is one of the few big pharmaceutical companies to have continued investing in discovery and development of new antibiotics through recent decades. Spero is a start-up focused on developing new treatments for serious bacterial infections. Large or small, companies know that pursuing truly novel scientific approaches to fighting infection could prove disruptive well beyond the laboratory.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
